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 Emerging risk factors for the development of atrial fibrillation (AF) include a variety of breathing disorders. 
For example, reduced lung function,1 and sleep-disordered breathing (SDB),2 have each been independently 
associated with increased risk of AF. Obstructive sleep apnea (OSA) was the strongest predictor of recurrent AF 
following catheter ablation.3 The severity of nocturnal hypoxaemia in patients with OSA independently predicted 
new-onset AF.4 However, transient arterial hypoxaemia, and hypercapnoea, such as occur during SDB may be 
associated with over-compensatory fluctuations in autonomic tone, intrathoracic pressures and cardiac 
haemodynamics, with possible atrial stretch and remodelling, each of which could predispose to AF. It is unclear 
whether hypoxaemia or hypercapnoea per se, i.e., in the absence of pathophysiological confounders or autonomic 
fluctuations, could cause atrial electrophysiological changes that could predispose to AF. 
 This question is addressed in the present issue of Heart Rhythm, in a study by Stevenson et al.5 They used an 
anaesthetised sheep model of hypoxaemia and of hypercapnoea, permitting the required control over physiological 
and pathophysiological variables, and the measurement of detailed invasive atrial electrophysiological parameters 
relating to reentry, a prominent electrophysiological mechanism of AF.6 The effective refractory period (ERP), 
conduction velocity (θ), and their temporal and spatial heterogeneity were examined in both atria. Acute 
hypoxaemia was induced by replacing O2 with N2 while maintaining normal CO2, which reduced arterial O2 
saturation (SaO2) to 80%. Neither this intervention, nor its acute reversal, significantly affected any of the 
electrophysiological measurements. By contrast, acute hypercapnoea, and its subsequent reversal, produced some 
intriguing changes in atrial electrophysiology. Hypercapnoea was induced with a re-breathing circuit while 
maintaining physiological SaO2 (>98%) which elevated arterial CO2 pressure (PaCO2) to 97 mmHg. This resulted 
in a progressive increase in atrial ERP which peaked, at steady-state hypercapnoea, with a 52% prolongation over 
the normocapnoeaic value. Atrial conduction delay was also increased by hypercapnoea, slowing θ by up to 27%. 
Hypercapnoea had no effect on the temporal or spatial heterogeneity of ERP or θ. Since the minimum pathlength 
for reentry, i.e., wavelength (λ), equals ERP x θ,6 these changes in ERP and θ should produce an overall 
lengthening of λ and thus potentially inhibit reentry. The vulnerability to extrastimulus-induced AF was assessed at 
that point, and AF could not be induced.5 However, strikingly, well after full reversal of hypercapnoea, while the 
ERP had recovered to pre-hypercapnoeaic levels, θ remained slowed by up to 22%, thus potentially shortening λ at 
that time. This coincided with an increased vulnerability to inducible AF. 
 A consideration of the potential underlying mechanisms and clinical implications of these findings raises 
some intriguing questions and possibilities for future study. For example, how did elevated PaCO2 increase ERP 
and slow θ, and why did the θ-slowing persist after the reversal of hypercapnoea while the ERP-increase did not? 
The mechanisms underlying the changes in ERP and θ were not specifically investigated.5 ERP is determined by 
Na+ current (INa) reactivation, which depends largely on action potential duration (APD). APD is determined by the 
relative magnitude of ion currents flowing during repolarisation.6 Hypercapnoea caused a significant decrease in 
serum pH, which reversed when PCO2 was returned to normal,5 and since the ERP changes were co-incident with 
these pH changes, one might suspect a causal link between them. However, this seems unlikely, since acidosis may 
actually shorten APD and ERP, by increasing a steady-state outward current.7 θ is determined by action potential 
maximum upstroke velocity (Vmax), which depends mainly on INa, and also by gap junction current (Igap), which 
reflects the degree of intercellular electrical coupling. Hypercapnoea caused a small increase in serum [K+].5 This 
likely resulted from the associated fall in pH, since CO2 forms carbonic acid thereby liberating H+, with consequent 
re-compartmentalisation of K+ and H+. It is unclear, therefore, why [K+] increased further when hypercapnoea and 
acidosis were reversed. Nevertheless, hyperkalaemia would shift the K+ electrochemical diffusion potential 
positively, partially depolarising the resting potential (Vm), thereby potentially slowing θ by reducing INa 
availability and Vmax. However, a study in guinea-pig atria8 suggests that the degree of [K+] increase observed,5 
either during hypercapnoea or following its reversal, may have been insufficient to account for the observed θ-
slowing; depolarising Vm by a maximum of only approximately 3 mV. Alternative explanations for the 
hypercapnoea-induced θ-slowing could include a reduction in Igap since, in canine ventricle, hypercapnoeaic-
acidosis slowed θ preferentially in the transverse direction, which may be determined by Igap rather than INa.9 
However, such an effect on Igap would need to persist for ≥2 hours after the hypercapnoea-reversal to explain the 
associated persistent θ-slowing5 via this mechanism. Why did hypoxaemia have no effect on atrial ERP or θ? 
Hypoxaemia may be expected to not affect atrial electrophysiology as long as PCO2 and pH are controlled, as 
here,5 and consistent with the majority of reports discussed by Stevenson et al.5 However, this may differ under 
more physiological conditions, in the presence of a functioning autonomic nervous system. Did the persistent θ-
slowing observed after the reversal of hypercapnoea actually cause the associated increased vulnerability to AF? 
This will require further investigation, since propagation of activation of the beat immediately preceding the onset 
of AF was not mapped, and non-reentrant activity could also have been involved. Furthermore, this increased 
susceptibility to AF may have been contributed to by a transient undershoot in λ, since the ERP was observed to 
transiently shorten by ~30 ms at the final stage of hypercapnoea-reversal (see Fig 2 in5). A similar undershoot in 
APD was reported to precede the onset of ventricular tachyarrhythmias resulting from post-ischaemic reperfusion.10 
Future studies might examine the precise temporal relationship between the increased AF vulnerability and changes 
in ERP and θ. 
 How do the SaO2 and PaCO2 values encountered in the Stevenson et al study5 compare with those found 
clinically, in patients with breathing disorders? A review of the literature indicates a wide variation in these values, 
depending on the type of breathing disorder and whether blood was sampled during wakefulness or sleep. In 
patients with OSA, episodes of hypoxaemia occur during sleep, with typical mean SaO2 nadirs in the range of 76-
83% saturation. In patients with chronic obstructive pulmonary disease (COPD), the typical waking SaO2 range is 
80-90%. This could fall further during sleep-related hypoxaemic episodes, typically to 65-80%, but in some cases 
to as low as <50%. Mean PCO2 in awake patients with COPD is typically in the range 45-53 mmHg. Nocturnal 
PCO2, however, is rarely reported, mainly because continuous measurement of transcutaneous PCO2 by electrode is 
unreliable. Post-sleep mean PCO2, in patients with OSA, typically is moderately higher than pre-sleep PCO2, e.g., 
54 versus 48 mmHg in one study, and 47 versus 45 mmHg in another. However, PCO2 could well peak 
momentarily at higher values during sleep. PCO2 values up to 55-59 mmHg can be attained during breath-holding 
in healthy adults, and in a single study of patients with severe COPD, in which PCO2 was measured during sleep 
via an in-dwelling arterial catheter, a mean maximum PCO2 of 63 mmHg was detected.11 Therefore, in the 
Stevenson et al study,5 the minimum mean SaO2 produced, of ~80%, is representative of typical minimum SaO2 
values in patients with SDB and/or COPD, suggesting that hypoxaemia per se might not contribute to the increased 
propensity to AF in such patients. The maximum mean PaCO2 produced,5 of ~97 mmHg, is substantially higher 
than peak levels expected in patients with SDB and/or COPD. However, intermediate, clinically relevant PCO2 
values, were found to prolong ERP.5 Nevertheless, it is unknown whether such intermediate values could also have 
slowed atrial θ, since θ was not measured until PaCO2 had reached ~97 mmHg. Moreover, it is also unknown 
whether the AF-promoting persistent θ-slowing plus ERP-shortening that was observed5 would occur following 
reversal of PCO2 from clinically relevant hypercapnoeaic levels, rather than from ~97 mmHg. If so, then such a 
mechanism would be most applicable to SDB, involving cyclical hypercapnoeaic episodes, rather than to COPD 
with chronically maintained hypercapnoea. It should be recognised that obstructive airways diseases cause 
combined hypoxaemia and hypercapnoea, and also that associated influences of increased adrenergic activity are 
expected to have wide-ranging and complex effects on atrial electrophysiology, intracellular Ca2+-handling, and 
propensity to AF (see12 for review).  
 Stevenson et al5 have provided provocative data on effects of hypercapnoea, and on a lack of effect of 
hypoxaemia, on atrial electrophysiology and susceptibility to AF, the mechanisms of which warrant further study. 
These data should be taken into account when considering the multiple mechanisms linking breathing disorders 
with the development of AF.  
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